Cardiff Oncology
CRDF
66 hedge funds and large institutions have $42.4M invested in Cardiff Oncology in 2016 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 12 increasing their positions, 26 reducing their positions, and 8 closing their positions.
100% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 8
42% more call options, than puts
Call options by funds: $1.29M | Put options by funds: $911K
14% more funds holding
Funds holding: 58 → 66 (+8)
10% less capital invested
Capital invested by funds: $47.3M → $42.4M (-$4.87M)
54% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 26
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.57M |
| 2 |
PCMI
Princeton Capital Management Inc
Princeton,
New Jersey
|
+$331K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$145K |
| 4 |
FHC
First Heartland Consultants
Lake St. Louis,
Missouri
|
+$109K |
| 5 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$95.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWVC
Morgens Waterfall Vintiadis & Co
New York
|
-$2.22M |
| 2 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
-$1.53M |
| 3 |
AIG
American International Group
New York
|
-$808K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$737K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$395K |
CRDF Hedge Fund Activity: Q2 2016 in Review
66 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q2 2016, worth a combined $42.4M — down 10% from $47.3M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new CRDF positions and 8 closed out — a net gain of 8 holders — while 12 added to existing stakes and 26 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $1.57M. The largest seller was Morgens Waterfall Vintiadis & Co, cutting an estimated $2.22M.
- 66 institutional investors held Cardiff Oncology (CRDF) as of Q2 2016, up from 58 in Q1 2016.
- Funds reported $42.4M of Cardiff Oncology stock for Q2 2016, down 10% quarter-over-quarter.
- 16 funds opened new Cardiff Oncology positions in Q2 2016 and 8 closed out, a net change of +8 holders.
- The largest Cardiff Oncology buyer in Q2 2016 was Morgan Stanley, an estimated $1.57M added.
- The largest Cardiff Oncology seller in Q2 2016 was Morgens Waterfall Vintiadis & Co, an estimated $2.22M sold.
Based on aggregated 13F filings for Q2 2016.